Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
NCT03334006
Digestive System Diseases, Infections
Vienna, Austria
View Trial DetailsNCT Number: NCT07388628
The objectives of this registry study are to:
1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects. 2. Further evaluate ARTICE® treatment efficacy. 3. Identify potential sub-groups, assess their risk-benefit- and safety profile. 4. Changes in SOFA score D0 to SOFA Score D7.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin, Magdeburg, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
standard lab and inflammatory biomarkers for exampample are: ferritine, total bilirubin, kreatinine, CRP, lactate, gammaglobuline, amount of the different blodd cell types, like neutrophils, lymphocytes
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
APACHE II is a clinical rating system for evaluating the severity of an illness and the risk of death in intensive care medicine; score includes information on the patient's current condition, age and concomitant diseases, values are collected over 24 hours, highest value is included in calcutaion; the score can be at minimum 0 points (lightly risk of death) and at maximum 71 (very high risk of death)
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
It is recorded whether the infection is viral, bacterial, or caused by fungi. And in case of bacterial infection it will be recorded weather, it is gram-positive or gram-negative bacterial infection.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
as physiological parameter will be measured heartrate in bpm
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
as physiological parameter will be measured systolic and diastolic blood pressure in mmHg.
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
as physiological parameter will be measured body temperature in °C
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
as physiological parameter will be measured mean arterial pressure in mmHG
Time frame: From enrollment up to 7 days after last ARTICE® treatment.
Contact information is provided by the study sponsor or research team.
Jens Altrichter, Dr. med.
CONTACT
Judith Hey, M. Sc.
CONTACT
Artcline GmbH
Industry
ARTISTRY - ARTICE® Therapy Registry Study
Acronym: ARTistry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03334006
Digestive System Diseases, Infections
Vienna, Austria
View Trial DetailsNCT07451886
Infections, Inflammation
Hong Kong
View Trial DetailsNCT07582926
Infections, Inflammation
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07300306
Critical Illness, Disease Attributes
Istanbul, Turkey (Türkiye)
View Trial Details